The New "Moda" in Multiple Myeloma: Modafakusp Alpha Targeting CD38 with Noa Biran, MD

Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Noa Biran, MD

Noa Biran, MD, is an associate professor in the Myeloma Division of the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey. She is actively involved in clinical research with a focus on high-risk disease and the role of minimal residual disease in multiple myeloma. Dr. Biran has presented a range of clinical work at international and national conferences such as the American Society of Hematology and the Society of Hematologic Oncology. She is widely published in hematology and oncology journals such as the American Journal of Hematology, Current Hematologic Malignancy Reports, and The Hemophilia Report. She has also co-authored the chapter “Oncologic Emergencies” in Essentials of Hospital Medicine: A Practical Guide for Clinicians. Prior to joining the John Theurer Cancer Center faculty, Dr. Biran served as Chief Fellow of Hematology and Medical Oncology at Icahn School of Medicine at Mount Sinai, New York. She also practiced in their internal medicine internship and residency and participated in numerous lecture series and training sessions for medical students, residents, and nurse practitioners. She received her medical degree from The George Washington University in Washington, D.C.